Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25637726 | 0.89 | APEX1 (0.58) | APEX1BLMTSHRBRD4MEN1 | |
| SCHEMBL563437 | 0.89 | APEX1 (0.58) | APEX1BLMTSHRBRD4MEN1 | |
| SCHEMBL2336934 | 0.83 | L3MBTL1 (0.40) | APEX1BLMCYP1A2BRD4MEN1 | |
| SCHEMBL3263411 | 0.82 | ALDH1A1 (0.40) | CYP1A2BRD4MEN1KMT2AL3MBTL1 | |
| SCHEMBL3263412 | 0.82 | ALDH1A1 (0.40) | CYP1A2BRD4MEN1KMT2AL3MBTL1 | |
| SCHEMBL15361830 | 0.77 | BRD4 (0.41) | APEX1BLMBRD4MEN1KMT2A | |
| SCHEMBL5009833 | 0.75 | L3MBTL1 (0.40) | APEX1BLMCYP1A2BRD4MEN1 | |
| SCHEMBL5009182 | 0.75 | BRD4 (0.41) | APEX1BLMBRD4MEN1KMT2A | |
| SCHEMBL563711 | 0.74 | CA1 (0.46) | CYP1A2TSHRBRD4MEN1KMT2A | |
| SCHEMBL15719198 | 0.74 | L3MBTL1 (0.39) | APEX1BLMCYP1A2BRD4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382203-B2 | N-carbamoylmethyl-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2016-07-05 | — | — | US | disclosed |
| US-9102615-B2 | N-Carbamoylmethy1-4-(R)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use | Joint Stock Company (JSC) “OLAINFARM” (LV) | 2015-08-11 | — | — | US | disclosed |
| US-20150216846-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | JOINT STOCK COMPANY (JSC) "OLAINFARM" (LV) | 2015-08-06 | — | — | US | disclosed |
| US-8492416-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB Biopharma SRL (BE) | 2012-02-09 | — | — | US | disclosed |
| US-8034958-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UOB Pharma, S.A. (BE) | 2011-10-11 | — | — | US | disclosed |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2010-09-02 | — | — | US | disclosed |
| US-7692028-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-04-06 | — | — | US | disclosed |
| EP-2013166-B1 | N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDINONE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE | AKCIJU SABIEDRIBA OLAINFARM (LV) | 2010-03-10 | — | — | EP | disclosed |
| US-20100022784-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | Joint Stock Company "Olainfarm" (LV) | 2010-01-28 | — | — | US | disclosed |
| EP-2013166-A2 | N-CARBAMOYLMETHYL-4(R)-PHENYL-2-PYRROLIDINONE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE | Akciju Sabiedriba "Olainfarm" (LV) | 2009-01-14 | — | — | EP | disclosed |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007104780-A2 | N- CARBAMOYLMETHYL- 4- (R) -PHENYL-2-PYRR0LIDIN0NE, METHOD OF ITS PREPARATION AND PHARMACEUTICAL USE | AKCIJU SABIEDRIBA 'OLAINFARM' (LV) | 2007-09-20 | — | — | WO | disclosed |
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | DIFFERDING EDMOND (BE) | 2005-08-04 | — | — | US | disclosed |
| US-6911461-B2 | For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse | UCB, S.A. (BE) | 2005-06-28 | — | — | US | disclosed |
| US-6806287-B2 | NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE | UCB, S.A. (BE) | 2004-10-19 | — | — | US | disclosed |
| US-6784197-B2 | SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS | UCB S.A. (BE) | 2004-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171187-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | APEX1 1453/4885BLM 4745/4885CYP1A2 3/4885 |
| US-20080097109-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | APEX1 1453/4885BLM 4745/4885CYP1A2 3/4885 |
| US-20100022784-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | PRMT6, CPS1, JMJD6 | APEX1 2185/4885BLM 4522/4885CYP1A2 351/4885 |
| US-20100222576-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, OGDH, CYP1A2 | APEX1 1453/4885BLM 4745/4885CYP1A2 3/4885 |
| US-20120035239-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | CYP1B1, OGDH, CYP1A2 | APEX1 1453/4885BLM 4745/4885CYP1A2 3/4885 |
| US-20150216846-A1 | N-Carbamoylmethyl-4-(R)-Phenyl-2-Pyrrolidinone, Method of its Preparation and Pharmaceutical Use | PRMT6, CPS1, JMJD6 | APEX1 2185/4885BLM 4522/4885CYP1A2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.